Study M602
Study name | Erabi H 2020 |
Title | Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis |
Overall design | The aim of this study was to use a metabolomic approach to extract metabolites involved in both the diagnosis of major depressive disorder (MDD) and the prediction of therapeutic response for escitalopram. Plasma metabolites of MDD patients (MDD group, n = 88) were compared with those in healthy participants (control group, n = 88). In addition, the metabolite levels were also compared between responders (responder group, at least 50% reduction in HRSD score after 6 weeks of escitalopram treatment, n = 29) relative to non-responders (non-responder group, n = 33) at baseline. |
Study Type | Type1; Type4; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD |
Sample size | 176 |
Tissue | Peripheral; Blood; Plasma; |
Platform | MS-based; LC-MS: LCMS 8060 instrument (Shimazu, Japan); |
PMID | |
DOI | |
Citation | Erabi H, Okada G, Shibasaki C, et al. Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis. Sci Rep. 2020;10(1):16822. |
Metabolite | Pyroglutamic acid; 3-Hydroxybutyric acid; L-Phenylalanine; L-Tryptophan; L-Valine; L-Glutamic acid; L-Serine; L-Threonine; L-Alanine; L-Asparagine; L-Tyrosine; L-Kynurenine; Kynurenic acid; Xanthurenic acid; |
